Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/33106
Title: | Effects of long-term treatment with dopamine receptor agonists and antagonists on terminal arbor size. | Authors: | Horne M.K.;Parish C.L.;Stanic D.;Drago J.;Borrelli E.;Finkelstein D.I. | Institution: | (Parish, Stanic, Drago, Finkelstein, Horne) Department of Medicine, Monash University, Monash Medical Centre, 246 Clayton Road, Clayton, Vic. 3168, Australia (Borrelli) Inst. de Genet. Biol. Molec. Cell., B.P. 163, 67404 Illkirch Cedex, France | Issue Date: | 18-Oct-2012 | Copyright year: | 2002 | Publisher: | Blackwell Publishing Ltd (9600 Garsington Road, Oxford OX4 2XG, United Kingdom) | Place of publication: | United Kingdom | Publication information: | European Journal of Neuroscience. 16 (5) (pp 787-794), 2002. Date of Publication: 2002. | Abstract: | This study demonstrates that pharmacological manipulation of the dopamine (DA) receptors can modulate the size of the axonal tree of substantia nigra pars compacta (SNpc) neurons in mice. Pharmacological blockade or genetic ablation of the D2 receptor (D2R) resulted in sprouting of DA SNpc neurons whereas treatment with a D2 agonist resulted in pruning of the terminal arbor of these neurons. Agents such as cocaine, that indirectly stimulate D2R, also resulted in reduced terminal arbor. Specific D1 agonists or antagonists had no effect on the density of DA terminals in the striatum. We conclude that the D2 receptor has a central role in regulating the size of the terminal arbor of nigrostriatal neurons. These findings have implications relating to the use of dopaminergic agonists in the management of Parkinson's disease and in controlling plasticity following injury, loss or transplantation of DA neurons. | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1046/j.1460-9568.2002.02132.x | PubMed URL: | 12372014 [http://www.ncbi.nlm.nih.gov/pubmed/?term=12372014] | ISSN: | 0953-816X | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/33106 | Type: | Article | Subjects: | animal tissue article *cell size controlled study corpus striatum drug effect long term care male mouse *nerve ending nonhuman priority journal rat *sprouting *substantia nigra animal experiment 2 ethoxy 1(2h) quinolinecarboxylic acid ethyl ester/pd [Pharmacology] 2,3,4,5 tetrahydro 7,8 dihydroxy 1 phenyl 1h 3 benzazepine/ip [Intraperitoneal Drug Administration] 2,3,4,5 tetrahydro 7,8 dihydroxy 1 phenyl 1h 3 benzazepine/pd [Pharmacology] 8 chloro 2,3,4,5 tetrahydro 3 methyl 5 phenyl 1h 3 benzazepin 7 ol hydrogen maleate/ip [Intraperitoneal Drug Administration] 8 chloro 2,3,4,5 tetrahydro 3 methyl 5 phenyl 1h 3 benzazepin 7 ol hydrogen maleate/pd [Pharmacology] benserazide plus levodopa/po [Oral Drug Administration] benserazide plus levodopa/pd [Pharmacology] bromocriptine/ip [Intraperitoneal Drug Administration] bromocriptine/pd [Pharmacology] cocaine/ip [Intraperitoneal Drug Administration] cocaine/pd [Pharmacology] cocaine/sc [Subcutaneous Drug Administration] dopamine 2 receptor blocking agent/pd [Pharmacology] dopamine 2 receptor stimulating agent/pd [Pharmacology] *dopamine receptor blocking agent/po [Oral Drug Administration] *dopamine receptor blocking agent/pd [Pharmacology] *dopamine receptor stimulating agent/ip [Intraperitoneal Drug Administration] *dopamine receptor stimulating agent/pd [Pharmacology] *dopamine receptor stimulating agent/sc [Subcutaneous Drug Administration] haloperidol/po [Oral Drug Administration] haloperidol/pd [Pharmacology] sulpiride/ip [Intraperitoneal Drug Administration] sulpiride/pd [Pharmacology] 2 ethoxy 1(2h) quinolinecarboxylic acid ethyl ester/ip [Intraperitoneal Drug Administration] *nerve ending nonhuman priority journal rat *sprouting *substantia nigra animal experiment animal tissue article *cell size controlled study corpus striatum drug effect long term care male mouse |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.